Skip to main content
Terug
CGON logo

CG Oncology, Inc. Common stock

Datakwaliteit: 100%
CGON
NASDAQ Healthcare Biotechnology
€ 63,84
▼ € 1,12 (-1,72%)
Marktkapitalisatie: 5,39B
Dagbereik
€ 62,80 € 64,66
52-Weeksbereik
€ 14,80 € 69,35
Volume
966.788
50D / 200D Gem.
€ 56,68 / € 39,90
Vorige Slotkoers
€ 64,96

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -33,5 0,3
P/B 7,2 2,9
ROE % -21,7 3,7
Net Margin % -3985,0 3,8
Rev Growth 5Y % -21,0 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 79,00 +23.7%
Low: € 70,00 High: € 93,00
Forward WPA
-€ 2,42
Omzet Sch.
15 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 6,52
€ 0,80 – € 17,44
1,4 B 3
FY2029 € 3,22
€ 0,39 – € 8,61
910 M 3
FY2028 € 0,22
-€ 1,72 – € 3,82
460 M 9

Belangrijkste Punten

Revenue declined -20,97% annually over 5 years
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -132,48M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 275,67%
Capital efficient — spends only 3,32% of revenue on capex

Groei

Revenue Growth (5Y)
-20,97%
Revenue (1Y)254,70%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-21,67%
ROIC-18,84%
Net Margin-3985,02%
Op. Margin-4722,13%

Veiligheid

Debt / Equity
0,01
Current Ratio24,63
Interest Coverage0,00

Waardering

P/E Ratio
-33,48
P/B Ratio7,16
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 254,70% Revenue Growth (3Y) 345,02%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -20,97% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4,04M Net Income (TTM) -161,00M
ROE -21,67% ROA -20,34%
Gross Margin -15,02% Operating Margin -4722,13%
Net Margin -3985,02% Free Cash Flow (TTM) -132,48M
ROIC -18,84% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 24,63
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -33,48 P/B Ratio 7,16
P/S Ratio 1334,24 PEG Ratio -0,42
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 5,39B Enterprise Value 5,36B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,04M 1,14M 204.000,0 191.000,0 10,36M
Net Income -161,00M -88,04M -48,61M -35,44M -12,84M
EPS (Diluted) -2,08 -1,41 -1,02 -0,66 -0,28
Gross Profit -607.000,0 1,14M 204.000,0 176.000,0 10,35M
Operating Income -190,77M -114,67M -55,45M -35,25M -12,61M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 791,59M 754,80M 199,30M 147,75M 58,69M
Total Liabilities 38,99M 21,42M 14,51M 22,57M 18,44M
Shareholders' Equity 752,60M 733,38M 184,79M 125,18M 40,25M
Total Debt 7,02M 238.000,0 1,03M 15,94M 15,13M
Cash & Equivalents 32,49M 257,07M 8,27M 88,14M 53,61M
Current Assets 759,48M 754,21M 194,12M 147,21M 58,41M
Current Liabilities 30,84M 21,37M 14,25M 15,43M 5,98M